Califf's Ethics Letter Lists Conflicts He Averted
This article was originally published in The Tan Sheet
The waiting periods that followed the end of the FDA commissioner nominee’s affiliations with several pharma firms already have expired.
You may also be interested in...
Learning To Drive The ‘Chariot’: FDA Deputy Califf’s New Role
Renowned clinical trialist and cardiologist will become deputy commissioner for medical products and tobacco, a complicated and challenging position.
US FDA Holds First Hybrid Meeting With Industry
A Type A meeting was held in-person with a virtual contingent, the FDA clarified to the Pink Sheet. Several other meeting requests received were eligible, but did not seek an in-person session.
US FDA Expands In-Person Meeting Eligibility, But So Far No Takers
The agency has not scheduled a hybrid meeting (with some staff meeting in person and others joining via videoconference) since allowing the format in mid-February.